Literature DB >> 8239575

The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

R Mayeux1, Y Stern, R Ottman, T K Tatemichi, M X Tang, G Maestre, C Ngai, B Tycko, H Ginsberg.   

Abstract

Apolipoprotein E (APO-E) binds to the beta-amyloid peptide and is present in senile neuritic plaques in Alzheimer's disease (AD). The epsilon 4 isoform of APO-E has been associated with both sporadic and familial late-onset AD, implying a causal role. Among patients and control subjects similar in age, gender, and ethnic group from the New York City community of Washington Heights-Inwood, we found that the odds ratio (OR) for AD associated with homozygosity for APO-epsilon 4 was 17.9 (95% confidence interval [CI], 4.6-69.8) and that associated with heterozygosity for APO-epsilon 4 was 4.2 (95% CI, 1.8-9.5) compared with persons with other APO-E genotypes. The association was stronger among patients with sporadic disease (OR = 10.3; 95% CI, 3.4-31.1) than among those with a family history of dementia in a first-degree relative (OR = 0.9; 95% CI, 0.1-13.5). The association between APO-epsilon 4 and AD did not differ according to age at onset (< 65 vs > or = 65), but appeared to vary across the 3 ethnic groups investigated (black, Hispanic, and white). Our data confirm the association between AD and APO-epsilon 4 and support the hypothesis that the APO-epsilon 4 allele either confers genetic susceptibility to AD or may be in linkage disequilibrium with another susceptibility locus. Ethnic variability in the allelic frequency of APO-epsilon 4 in the elderly warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239575     DOI: 10.1002/ana.410340527

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  78 in total

1.  Risk of dementia in parents of probands with and without the apolipoprotein E4 allele. The EVA study.

Authors:  S Danet; T Brousseau; F Richard; P Amouyel; C Berr
Journal:  J Epidemiol Community Health       Date:  1999-07       Impact factor: 3.710

2.  Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Authors:  C Haas; P Cazorla; C D Miguel; F Valdivieso; J Vázquez
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

4.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

Review 5.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful.

Authors:  J Tian; R S Bucks; J Haworth; G Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

7.  Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers.

Authors:  D St Clair; M Rennie; E Slorach; J Norrman; C Yates; A Carothers
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

Review 8.  A potential role for apoptosis in neurodegeneration and Alzheimer's disease.

Authors:  C W Cotman; A J Anderson
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

9.  Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid.

Authors:  Simona Vuletic; Ge Li; Elaine R Peskind; Hal Kennedy; Santica M Marcovina; James B Leverenz; Eric C Petrie; Virginia M-Y Lee; Douglas Galasko; Gerard D Schellenberg; John J Albers
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 10.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.